CPHI Online Newsletter: Issue 17

???THE LATEST PHARMA NEWS YOU NEED TO START YOUR WEEK???

The?CPHI Online?Weekly Newsletter brings you the latest bite-size?#pharma?news straight to your LinkedIn inbox. Want to keep your finger on the pulse? ? Look no further ??subscribe here.

Biopharmaceutical company Provention Bio, Inc. (Red Bank, USA) announced their collaborative agreement with Sanofi U.S. (Bridgewater, USA) for the launch of Provention’s lead investigational drug candidate teplizumab, a monoclonal antibody (mAb) developed for the delay of clinical Type I diabetes ???? Read on here.

Connect to Frankfurt ??

As part of our conference track on Manufacturing Excellence, discover the all-encompassing, integrated platforms for an efficient bispecific molecule production method, from cell line development and tox screenings through to cGMP manufacturing, generating high quality clinical bulk drug substances under accelerated timelines.?Séverine Fagète, VP, Cell Line Development Services at Selexis (Geneva, Switzerland), and Brandon Brino (Durham, USA), Process Development Scientist and Group Leader at KBI Biopharma, present an overview of a streamlined process for the production of bispecific molecules.?????Read on here.

Merck in Martillac

German science and technology company Merck's latest 2,700 square metre commercial facility has officially opened in Martillac, France as part of its new Millipore CTDMO Services for monoclonal antibodies and other recombinant proteins. ????Read on here.

Finally - we speak with Jimin Han, Director of Climate Change in Business Strategy Team at?Samsung Biologics (Incheon, South Korea), in an exclusive interview where we discuss trends in the global biologics market, the biggest opportunities and challenges for this sector, and the growing consciousness surrounding sustainable practices for biologics developers and manufacturers...???? For more details read on here.

For regular news please?Subscribe?to this newsletter, to stay updated with all?CPHI Online?news.